RSS Feeds
Lincomycin Versus Erythromycin: A Choice or an Echo
- EUGENE SANDERS, M.D.
- Requests for reprints should be addressed to Eugene Sanders, M.D., University of Florida College of Medicine, Gainesville, FIa. 32601
SUMMARY
Lincomycin shares many of the pharmacologic, toxicologic, and antibacterial properties of erythromycin. It offers few therapeutic advantages in comparison with erythromycin when the infecting microorganism is susceptible to both drugs. For the present lincomycin is clearly preferred only when the patient is intolerant to erythromycin, the infecting agent is insusceptible to erythromycin, or possibly when lincomycin-susceptible microorganisms are located within bone.
Article and Author Information
-
From the Department of Medicine and Microbiology, University of Florida College of Medicine, Gainesville, FIa.
-
This study was supported in part by research and training grants AI-06514 and 5-TI-AI-0128, National Institutes of Health, Bethesda, Md.
-
Dr. Sanders was supported by Research Career Development Award I-K3-AI 38636, National Institutes of Health, Bethesda, Md.; and by a Scholarship in Academic Medicine, John and Mary Markle Foundation, New York, N. Y.
-
- Received October 7, 1968.
- Accepted November 26, 1968.
